Leah Kuntz

According to new data, NeuroStar Advanced TMS helped nearly 60% of adolescents with major depressive disorder.

Check out new results of a pharmacokinetics study of AD04, an investigational therapeutic agent for the treatment of alcohol use disorder in patients with heavy drinking.

The FDA has granted clearance to the Horizon Inspire transcranial magnetic stimulation system to treat major depressive disorder, obsessive-compulsive disorder, and anxious depression.

Emraclidine once-daily, oral monotherapy treatment for adults with schizophrenia experiencing acute psychotic symptoms, failed to meet the primary endpoints in the 2 phase 2 EMPOWER trials.

New positive results demonstrate the efficacy and safety of lumateperone (Caplyta) 42 mg for the prevention of relapse in adult patients with schizophrenia.

A new collaboration to address sleep disturbances associated with cognitive impairment, an unmet need.

How can we lessen fatal interactions between individuals with mental illness and police? The best possible avenue is partnership and cooperation between mental health clinicians and law enforcement.

Do you want to be featured in our online series and potentially in print? Check out our November theme!

Posters from Psych Congress confirm the durability of long-term treatment with xanomeline/trospium (Cobenfy).

Need CME credit? Check out these articles.

The CDC just released new data that highlight issues around adult ADHD prevalence, diagnosis, and treatment.

The FDA has granted Fast Track designation to liafensine for the treatment of patients with treatment-resistant depression.

Do you want to be featured in our online series and potentially in print for an upcoming Special Report? Check out our October theme!

Multiple sites are now enrolling participants in a phase 2 clinical trial to evaluate SPG302, the first synaptic regenerative therapy for schizophrenia.

New data informs clinicians of how best to switch patients from a once-monthly subcutaneous injection of RBP-7000 (Perseris) to risperidone (Uzedy), an extended-release injectable suspension of risperidone for subcutaneous use every 1 or 2 months for the treatment of schizophrenia in adults.

Check out new positive efficacy, safety, and tolerability results from the phase 3 SOLARIS trial evaluating TEV-‘749 in adult patients diagnosed with schizophrenia.

A new analysis from a 3-year open-label extension study revealed that treatment with deutetrabenazine was associated with long term improvement of symptoms of tardive dyskinesia.

Enter your email to check out this complicated case!

A new study of adult emergency department admissions found that individuals taking high doses of amphetamine—like Adderall—have a 5-fold increased risk for developing psychosis or mania.

Learn more about the latest research related to 9/11 trauma and other psychiatric comorbidities.

DaylightRx becomes the very first FDA-cleared digital treatment for generalized anxiety disorder.

Abbott has initiated the TRANSCEND study to evaluate the use of deep brain stimulation to manage treatment-resistant depression.

Write to us now to be part of our series on forensic psychiatry!

Tomorrow, August 31, is Overdose Awareness Day. What can you be doing to help prevent overdose deaths?

What is new in research on major depressive disorder?

The first investigational, oral, muscarinic M4 selective agonist in development for the treatment of schizophrenia sees positive phase 2 results in the lowest tested dose.

New phase 1b results of VLS-01, an oral transmucosal film formulation of DMT, show ‘psychologically meaningful’ improvement for patients with treatment-resistant depression.

At least 1 in 2 people experience trauma at some point in their life, and a subset of those individuals will develop PTSD.

Write to us now to be part of our series on treatment updates this month.

The US Food and Drug Administration has approved Erzofri, a paliperidone palmitate extended-release injectable suspension for the treatment of adults with schizophrenia and schizoaffective disorder.